Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b Study of Danuglipron (PF-06882961) in Adults with Obesity
NCT04707313Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of danuglipron in obesity, sponsored by Pfizer. Started Jan 2021; status: completed.
02
Drugs
danuglipron
03
Conditions
obesity
Beyond the preview
Go deeper on NCT04707313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707313.